A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update

被引：0

作者：

Ahn, M-j.

Cho, B. C. ^{[1
]}

Kim, T. M. ^{[2
]}

Han, J-y.

Kim, C. ^{[3
]}

Shim, B. ^{[4
]}

Drilon, A. ^{[5
,6
]}

Blumenschein, G. ^{[7
]}

Villaruz, L. ^{[8
]}

Gray, J. E. ^{[9
]}

Pujol, J-l. ^{[10
]}

Lena, H. ^{[11
]}

Moro-Sibilot, D. ^{[12
]}

Perez, J. ^{[13
]}

Modi, D. A. ^{[13
]}

Park, J. S. ^{[13
]}

Patel, S. ^{[13
]}

Li, S. ^{[13
]}

Kim, E. ^{[13
]}

Magnan, H. ^{[13
]}

机构：

[1] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[2] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea

[3] Georgetown Univ, Med Oncol, Hematol Oncol, Washington, DC USA

[4] Catholic Univ Korea, Dept Med Oncol, Seoul, South Korea

[5] Weill Cornell Med Ctr, Mem Sloan Kettering Canc Ctr, New York, NY USA

[6] Weill Cornell Med Ctr, New York, NY USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[8] Univ Pittsburgh Med Ctr UPMC, Hillman Canc Ctr, Dept Oncol, Pittsburgh, PA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Tampa, FL USA

[10] Ctr Hosp Reg Univ CHRU Montpellier Arnaud Villeneu, Dept Thorac & Vasc Surg, Montpellier, France

[11] Univ Rennes, Dept Oncol, Rennes, France

[12] Ctr Hosp Univ Grenoble, F-38000 Grenoble, France

[13] Regeneron Pharmaceut Inc, Med Oncol, Tarrytown, NY USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.754

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

721TiP

引用

页码：S1673 / S1674

页数：2